VIDEO: Gilteritinib ‘remains active’ in AML patients who receive prior TKI therapy
Click Here to Manage Email Alerts
Patients with relapsed or refractory acute myeloid leukemia who received prior tyrosine kinase inhibitor – midostaurin or sorafenib – achieved remission with gilteritinib, an FLT3 inhibitor, according to data presented at ASH Annual Meeting and Exposition.
“What we show is that gilteritinib [Xospata, Astellas] remains active in patients who had prior TKI therapy,” Alexander E. Perl, MD, of Penn Medicine, told Healio in a video interview. “In the group that we’re most interested in – ie, those who receive front-line midostaurin [Rydapt, Novartis] and had no response to it – the data suggest that we should be using gilteritinib in that setting, and the outcomes are equivalent to those who have not had prior midostaurin. Overall, we show that gilteritinib remains active and it seems to be the preferred approach.”
Collapse
Perl AE, et al. Abstract 334. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.
Click Here to Manage Email Alerts